Donate

Webinar: What’s New In Mantle Cell Lymphoma

Hosted by Lymphoma Australia and Professor Constantine Tam.

Join us for our next educational webinar tailored for patients, families, and carers affected by lymphoma.

This session will provide valuable insights into Mantle Cell Lymphoma, including current management strategies, recent treatment developments, and what the future of care may look like.

Event Details

Topic: What’s New in Mantle Cell Lymphoma
Date: Monday, 21st July
Time: 4pm (AEST)
Location: Online (Zoom link will be sent upon registration)

Registration is free and open to all.

Guest Speaker

Professor Constantine Tam
Head of Lymphoma Service, Clinical Haematologist – Alfred Health
Professor of Haematology – Monash University

Professor Constantine (Con) Tam is a leading expert in lymphoma and an internationally recognised Clinical Haematologist. He currently heads the Lymphoma Service at Alfred Health and holds a Professorship at Monash University.

Professor Tam completed his medical training at the University of Melbourne and went on to dual specialise in Haematology and Haematopathology. His training includes a Leukemia Fellowship at the world-renowned MD Anderson Cancer Centre.

Prior to his current role, he served for over a decade as the Disease Group Lead for Low Grade Lymphoma and CLL at Peter MacCallum Cancer Centre.

A pioneer in the development of targeted therapies, Professor Tam led the global development of the BTK inhibitor zanubrutinib and conducted the first international trial combining ibrutinib and venetoclax—results of which were published in the New England Journal of Medicine.

He also served as the Australian lead for the pivotal Tisagenlecleucel study, which helped establish CAR T-cell therapy as a standard treatment for diffuse large B-cell lymphoma.

With over 300 peer-reviewed publications and more than 27,000 citations, Professor Tam’s research continues to shape the future of lymphoma care worldwide. He is also an Associate Editor for Blood Advances.

Register Now

This is a free online event, but registration is essential to secure your spot.



Download Flyer

There is limited availability for this event, so secure your spot quickly.
This event has already taken place.
Details
Date: Monday 21st of July 2025
Time: 4:00pm AEST - 5:30pm AEST

 

Registration is free and open to all.

For any questions, please email us at nurse@lymphoma.org.au
Register to attend
Watch recording
Download Flyer

Support and information

Patient Online Forum

Find Out More

Order Our Resources

Find Out More

Fundraise for us

Get started

Cart
Checkout - $0.00
  • 0
  • 1

Contact Lymphoma Australia Today!

Patient Support Hotline

General Enquiries

Please note: Lymphoma Australia staff are only able to reply to emails sent in English language.

For people living in Australia, we can offer a phone translation service. Have your nurse or English speaking relative call us to arrange this.

Useful Definitions

  • Refractory: This means the lymphoma does not get better with treatment. The treatment didn’t work as hoped.
  • Relapsed: This means the lymphoma came back after being gone for a while after treatment.
  • 2nd line treatment: This is the second treatment you get if the first one didn’t work (refractory) or if the lymphoma comes back (relapse).
  • 3rd line treatment: This is the third treatment you get if the second one didn’t work or the lymphoma comes back again.
  • Approved: Available in Australia and listed by the Therapeutics Goods Administration (TGA).
  • Funded: Costs are covered for Australian citizens. This means if you have a Medicare card, you shouldn’t have to pay for the treatment.[WO7]

You need healthy T-cells to make CAR T-cells. For this reason, CAR T-cell therapy cannot be used if you have a T-cell lymphoma – yet.

For more information on CAR T-cells and T-cell lymphoma click here. 

Special Note: Although your T-cells are removed from your blood for CAR T-cell therapy, most of our T-cells live outside of our blood – in our lymph nodes, thymus, spleen and other organs.